Study #2024-1994
Phase 1/2 study of HLD-0915 in patients with metastatic castration resistant prostate cancer (mCRPC)
MD Anderson Study Status
Enrolling
Treatment Agent
HLD-0915
Description
Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer Metastatic Disease, Prostate Cancer (Adenocarcinoma)
Study phase:
Physician name:
Andrew Hahn
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.